Media Articles Related to Lupron Depot (Leuprolide)
Additional link found between endometriosis and ovarian cancer
Source: Immune System / Vaccines News From Medical News Today [2014.04.08]
Some women with endometriosis, a chronic inflammatory disease, are predisposed to ovarian cancer, and a genetic screening might someday help reveal which women are most at risk, according to a...
How can diagnosis for endometriosis be improved?
Source: Medical Students / Training News From Medical News Today [2014.03.12]
This week sees Endometriosis Awareness Day's 'Million Women March.' Endometriosis is frequently misdiagnosed. But how can understanding of this common condition be improved?
Gene changes suggest epigenetic modification in endometriosis
Source: Fertility News From Medical News Today [2014.03.11]
Changes to two previously unstudied genes are the centerpiece of a new theory regarding the cause and development of endometriosis, a chronic and painful disease affecting 1 in 10 women.
Source: MedicineNet letrozole Specialty [2013.03.19]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/19/2013 12:00:00 AM
Endometriosis Quiz: Test Your Medical IQ
Source: MedicineNet letrozole Specialty [2012.03.07]
Title: Endometriosis Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 3/2/2012 12:34:00 PM
Last Editorial Review: 3/7/2012 5:03:32 PM
Published Studies Related to Lupron Depot (Leuprolide)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. [2011.09]
PURPOSE: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial... CONCLUSIONS: Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. [2011.06]
The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial...
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain...
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.11]
OBJECTIVE: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women... They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance.
Clinical Trials Related to Lupron Depot (Leuprolide)
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy [Active, not recruiting]
Primary Objective :
- The primary objective of the study is to compare progression-free survival (PSA
progression after systemic treatment, radiologically or histologically documented
progression after systemic treatment or death from any cause, whichever occurs first),
using a 2x2 factorial design among treatment groups as follows:
- Immediate treatment following prostatectomy versus deferred treatment at the time
- Docetaxel q3w plus leuprolide acetate versus leuprolide acetate alone
Secondary Objectives :
- To compare the 5-year overall, cancer-specific and metastasis-free survival
(metastasis-free survival based on time to clinical evidence of metastasis evidenced by
physical exam or radiologically on bone scan or CT scan) after systemic treatment
between the groups defined as follows:
- Immediate treatment following prostatectomy versus deferred treatment
- Docetaxel q3w plus leuprolide acetate versus leuprolide acetate alone
- To compare the safety and tolerability between Docetaxel in combination with leuprolide
acetate and leuprolide acetate alone.
- To evaluate quality of life as measured by the FACT-P questionnaire.
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases [Recruiting]
The purpose of this study it to determine whether the use of a gonadotropin releasing
hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in
women with rheumatic diseases will provide greater ovarian protection than placebo.
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [Completed]
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone
levels are measured at set intervals to determine if Eligard is equal or better then Lupron
or Zoladex in advanced Prostate Cancer patients.
Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation [Recruiting]
- One way to treat certain cancers of the blood and immune system is to give a patient
stem cells from the bone marrow of a donor whose genes are very similar but not
identical to the patient's. One problem with these transplants is that the new immune
cells may not work as well in the recipient as they did in the donor. The result may be
that the immune system will not work as well. This can increase the risk of severe
infections and other complications.
- Researchers are studying the use of drugs that lower hormone levels and may allow the
immune system to recover in a way that improves white blood cell function. In this
study they will be looking at the drug lupron, a drug that lowers estrogen or
testosterone levels, to see if it might improve the function of the newly transplanted
- To determine whether lupron improves immune system function after bone marrow
transplantation from a donor with similarities in their immune cells (matched to each
- To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug FLT in
imaging studies. FLT will be used to image the immune system function in patients who
have received bone marrow from the donor.
- People between 15 (or as young as 9 in those who have gone through puberty) and 40
years of age. These patients must have acute myelogenous leukemia, acute lymphocytic
leukemia, or high-risk myelodysplastic syndrome. They must also be eligible for a bone
- Genetically similar donors for the patients who are eligible for a transplant.
- People taking part in the study will be screened with a physical examination, medical
history, blood and urine tests, and imaging studies. Patients who are not in remission
or who require a bone marrow donor search may receive chemotherapy first.
- Donors will provide bone marrow for transplant according to standard bone marrow
transplant (BMT) procedures.
- All women and half of the men will receive regular lupron doses 2 weeks before BMT to
suppress hormone function.
- All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy
before the bone marrow transplant (depending on age). Recipients will also receive
other drugs to prevent transplant rejection and other complications of transplantation.
- Recipients will be monitored in the hospital for 4 weeks after transplant with blood
tests and other studies.
- Some recipients will have an imaging study with FLT during the protocol. These imaging
studies will take place before the transplant, on days 5 and 28 after transplant, and
at a later time to be determined by the study researchers.
- Following discharge, participants will be monitored closely for up to 6 months, with
regular but less frequent followup visits for at least 5 years. Study-related
medications, including vaccinations for the new immune system, will be provided by the
National Institutes of Health during the hospital stay and after discharge.
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF [Completed]
This prospective randomized trial evaluates whether one can predict which infertile women
with endometriosis who are candidates for in vitro fertilization will benefit from prolonged
therapy with a GnRH agonist by the determination of the absence of endometrial expression of
the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which
all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for
in vitro fertilization and then undergo randomization to a three month course of a depot
preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian
stimulation or standard therapy. prio
Reports of Suspected Lupron Depot (Leuprolide) Side Effects
Hot Flush (180),
Prostate Cancer Metastatic (59),
Insomnia (58), more >>